Evidence map›Paper›PMID 41082075›Full record

ReviewAdvances in therapy2025

The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion.

Salvatore Tafuto, Secondo Lastoria, Francesco Panzuto, Lorenzo Antonuzzo, Davide Campana, Sara Cingarlini, Mauro Cives, Diego Ferone, Angelina Filice, Dario Giuffrida and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Long-term toxicity of tandem radioligand therapy using [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Salvatore TafutoDepartment of Sarcomas and Rare Tumors, Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale, Naples, Italy.
Secondo LastoriaDepartment of Nuclear Medicine and Therapy With Radionuclides, Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale, ENETS Center of Excellence, Naples, Italy.
Francesco PanzutoDepartment of Surgical-Medical Sciences and Translational Medicine, Sapienza University of Rome, Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy. francesco.panzuto@uniroma1.it.
Lorenzo AntonuzzoDepartment of Experimental Clinical Medicine, University of Florence, Florence, Italy.
Davide CampanaDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, Università degli Studi di Bologna, Bologna, Italy.
Sara CingarliniDepartment of Engineering for Precision Medicine, Oncology Unit, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
Mauro CivesInterdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy.
Diego FeroneEndocrinology Unit, IRCCS Ospedale Policlinico San Martino, Università degli Studi di Genova, Genoa, Italy.
Angelina FiliceNuclear Medicine Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Dario GiuffridaDepartment of Medical Oncology, Istituto Oncologico del Mediterraneo, Viagrande, Italy.
Marco MaccauroDepartment of Nuclear Medicine, Fondazione IRCCS Istituto Nationale Dei Tumori, Milan, Italy.
Stefano PartelliDepartment of Pancreatic Surgery, IRCCS Ospedale San Raffaele, Milan, Italy.
Nicola FazioDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) comprise a heterogeneous group of clinically diverse tumors; their management is based on clinical characteristics. International guidelines recommend standard-dose somatostatin analogues (SSAs) as first-line treatment for advanced, low-grade G1 and "low" G2 NETs. No standard-of-care treatment is determined for "high" G2 and G3 NETs. Radioligand therapy (RLT) with [

Indexed as

Intestinal NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsRadiopharmaceuticalsStomach NeoplasmsDisease ProgressionHumansItalyNeoplasm GradingOctreotideOrganometallic CompoundsPractice Guidelines as TopicProgression-Free SurvivalRandomized Controlled Trials as TopicReceptors, SomatostatinSomatostatinlutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticalsReceptors, SomatostatinSomatostatinExpert opinionGastroenteropancreaticGEP-NETsNETTER-2Neuroendocrine neoplasm

Identifiers

PMID41082075
PMCPMC12618337

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.